<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02962479</url>
  </required_header>
  <id_info>
    <org_study_id>EK001</org_study_id>
    <nct_id>NCT02962479</nct_id>
  </id_info>
  <brief_title>Is the Human Microbiome Altered in Patients With Axial Spondyloarthritis?</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eyal Kedar</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Lawrence Health System</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to compare biological communities in stool samples obtained from age, diet&#xD;
      and BMI-matched subjects in five study groups: subjects with ankylosing spondylitis (AS)&#xD;
      never treated with tumor necrosing factor (TNF) inhibitors, subjects with ankylosing&#xD;
      spondylitis previously or currently treated with TNF inhibitors, subjects with&#xD;
      non-radiographic axial spondyloarthritis (nrSpA) never treated with tumor necrosing factor&#xD;
      (TNF) inhibitors, subjects with non-radiographic axial spondyloarthritis previously or&#xD;
      currently treated with TNF inhibitors and healthy participants.&#xD;
&#xD;
      The differences in fecal microbiota composition will be explored using shotgun metagenomic&#xD;
      sequencing through the University of Washington. The investigators predict that this study&#xD;
      will confirm a significant difference between the fecal microbiota composition (FMC) of both&#xD;
      AS and nrSpA patients and controls.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">October 2017</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Weighted and unweighted UniFrac distances between stool samples from the five study groups</measure>
    <time_frame>Within 1 month of baseline visit</time_frame>
  </primary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Axial Spondyloarthritis</condition>
  <condition>Ankylosing Spondylitis</condition>
  <arm_group>
    <arm_group_label>TNF blocker-naïve ankylosing spondylitis patients</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>TNF blocker-exposed ankylosing spondylitis patients</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>TNF blocker-naïve nrSpA patients</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>TNF blocker-exposed nrSpA patients</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Participants</arm_group_label>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Subjects will have the option to provide additional consent for specimens to be retained by&#xD;
      the research team indefinitely for research purposes. These samples will be identified only&#xD;
      by the numeric study ID; no personally identifying information will be associated with the&#xD;
      retained samples. The samples could be used to make new products, tests or findings, which&#xD;
      may have value and may be developed and owned by the research team and/or others.&#xD;
      Investigators will not be able to provide subjects with results from any future research that&#xD;
      is done using their samples.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        At least 50 subjects, male and female, aged 18 or older, will be recruited to the study and&#xD;
        assigned to one of five groups:&#xD;
&#xD;
          1. Ten TNF blocker-naïve ankylosing spondylitis patients&#xD;
&#xD;
          2. Ten TNF blocker-exposed ankylosing spondylitis patients&#xD;
&#xD;
          3. Ten TNF blocker-naïve nrSpA patietns&#xD;
&#xD;
          4. Ten TNF blocker-exposed nrSpA patients&#xD;
&#xD;
          5. Ten healthy age, diet and BMI-matched controls Inclusion and exclusion criteria will&#xD;
             vary by study group. It is anticipated that the TNF-blocker naïve groups will be the&#xD;
             most difficult to recruit, so these groups will serve as the baseline for age and diet&#xD;
             matching for the other two groups. Up to seventy (70) additional TNF-treated axial SpA&#xD;
             and healthy subjects may be asked to complete the dietary questionnaire, but will not&#xD;
             provide stool samples unless age, diet and BMI-matched with a TNF-blocker-naïve axial&#xD;
             SpA subject.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Able to provide informed consent&#xD;
&#xD;
          -  Male or Female patients ≥18 years of age&#xD;
&#xD;
          -  Additional Inclusion Criteria based on cohort&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current use of any pain-relieving medications other than NSAIDs, APAP and/or opioids&#xD;
&#xD;
          -  Corticosteroid therapy or probiotic exposure within the last two weeks&#xD;
&#xD;
          -  Antibiotic exposure within the past two months&#xD;
&#xD;
          -  History of psoriasis or inflammatory bowel disease or reactive arthritis or any other&#xD;
             chronic rheumatologic disease&#xD;
&#xD;
          -  Active infection&#xD;
&#xD;
          -  History of hepatitis B or C or HIV&#xD;
&#xD;
          -  Active cancer or history of colon cancer or any form of chemotherapy or radiation&#xD;
             within the past year&#xD;
&#xD;
          -  Celiac disease&#xD;
&#xD;
          -  Use of proton pump inhibitors within the prior two months&#xD;
&#xD;
          -  History of clostridium difficile&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Active diarrhea (defined as a decrease in fecal consistency lasting four or more&#xD;
             weeks)&#xD;
&#xD;
          -  Additional Exclusion Criteria based on cohort&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>St. Lawrence Health System</name>
      <address>
        <city>Potsdam</city>
        <state>New York</state>
        <zip>13676</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <study_first_submitted>November 8, 2016</study_first_submitted>
  <study_first_submitted_qc>November 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2016</study_first_posted>
  <last_update_submitted>November 9, 2016</last_update_submitted>
  <last_update_submitted_qc>November 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>St. Lawrence Health System</investigator_affiliation>
    <investigator_full_name>Eyal Kedar</investigator_full_name>
    <investigator_title>Rheumatologist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylitis</mesh_term>
    <mesh_term>Spondylitis, Ankylosing</mesh_term>
    <mesh_term>Spondylarthritis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

